There were no significant differences in the percentage of patients with moderate-to-severe active Crohn 's disease who achieved clinical responses ( Response-70 ) or clinical remission after 4 weeks ' administration of tofacitinib ( 1 , 5 , or 15 mg ) or placebo twice daily .